EN PL
ORIGINAL PAPER
 
KEYWORDS
TOPICS
ABSTRACT
Introduction:
There is limited knowledge on cognitive performance in Behçet’s disease (BD), the majority of which come from patients with neuro-Behçet’s disease. However, the influence of BD on cognitive function in patients without neurological involvement is still not well understood. The aim of the study was to determine the frequency of cognitive involvement in BD patients without evident neuropsychiatric symptoms and to identify associated clinical variables in those patients.

Material and methods:
Forty BD patients who fulfilled the diagnostic International Criteria for Behçet ‘s Disease (ICBD) without obvious neuropsychiatric manifestations were studied and compared with forty healthy controls matched for age, sex, and education. A comprehensive medical history, rheumatological, neurological, psychiatric, and psychometric assessment were applied for all patients. Behçet’s disease Current Activity Form (BDCAF) was used to assess disease activity. For patients as well as controls, validated Arabic versions of the Wechsler Adult Intelligence Scale-Revised and Wechsler Memory Scale-Revised were used for assessment of cognitive function. Anxiety and depression were additionally assessed for both groups using the anxiety and depression subdivisions of the Arabic Version of Symptom Checklist 90 Revised.

Results:
Cognitive impairment was identified in 37.5% of BD patients compared to none of the controls. Memory represents the cognitive domain most frequently affected. Cognitive involvement was significantly associated with current corticosteroid use and depression as measured by SCL-90-R. On the other hand, neither the activity of the disease nor the level of anxiety was associated with cognitive involvement.

Conclusions:
Cognitive dysfunction is reported in BD patients distinctly and independently of clinically overt neurologic involvement. Prevalence of cognitive impairment in patients with BD is strikingly high at 37.5%, whereas the control group exhibited no such signs. Psychological assessment should be performed for every BD patient to reveal any cognitive involvement. It is highly recommended to encourage psychological intervention to prevent any further deterioration, especially in patients who are experiencing depression or currently using corticosteroids.

 
REFERENCES (43)
1.
Sakane T, Takeno M, Suzuki N, Inaba G. Behçet’s disease. N Engl J Med 1999; 341: 1284–1291. DOI: 10.1056/NEJM­199910213411707.
 
2.
Alpsoy E, Bozca BC, Bilgic A. Behçet disease: an update for dermatologists. Am J Clin Dermatol 2021; 22: 477–502. DOI: 10.1007/s40257-021-00609-4.
 
3.
Fisher CA. Psychological and neurocognitive impact of Behect’s disease. Int J Vasc Surg Med 2020; 6: 001–008. DOI: 10.17352/2455-5452.000036.
 
4.
Fisher CA, Bernard C. A systematic review of neurocognitive functioning in Behçet’s disease. Neuropsychol Rev 2019; 29: 498–521, DOI: 10.1007/s11065-019-09416-5.
 
5.
Cavaco S, da Silva AM, Pinto P, et al. Cognitive functioning in Behçet’s disease. Ann N Y Acad Sci 2009; 1173: 217–226, DOI: 10.1111/j.1749-6632.2009.04670.x.
 
6.
Monastero R, Camarda C, Pipia C, et al. Cognitive impairment in Behçet’s disease patients without overt neurological involvement. J Neurol Sci 2004; 220: 99–104. DOI: 10.1016/ j.jns.2004.02.021.
 
7.
Dutra LA, de Souza AW, Alessi H, et al. Cognitive impairment in Brazilian patients with Behçet’s disease occurs independently of neurologic manifestation. J Neurol Sci 2013; 327: 1–5, DOI: 10.1016/j.jns.2013.01.024.
 
8.
Sucullu Karadag Y, Kurt P, Sahin K, et al. Cognitive impairment not only in neuroBehcet but also for all Behcet disease phenotypes. J Neurol Sci 2014; 31: 511–520, DOI: 10.1136/pn-2023-003875.
 
9.
International Team for the Revision of the International Criteria for Behçet’s Disease (ITR-ICBD). The International Criteria for Behçet’s Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. J Eur Acad Dermatol Venereol 2014; 28: 338–347, DOI: 10.1111/jdv.12107.
 
10.
Yesilot N, Shehu M, Oktem-Tanor O, et al. Silent neurological involvement in Behçet’s disease. Clin Exp Rheumatol 2006; 24 (5 Suppl 42): S65–70. Erratum in: Clin Exp Rheumatol 2007; 25: 507–508.
 
11.
American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th ed. American Psychiatric Association, Washington, D.C., APA 1994; 873.
 
12.
Bhakta BB, Brennan P, James TE, et al. Behçet’s disease: evaluation of a new instrument to measure clinical activity. Rheumatology (Oxford) 1999; 38: 728–733, DOI: 10.1093/ rheumatology/38.8.728.
 
13.
El-Behairy AA. The Symptom Checklist-90-R. El-Nahda El-Misrya, Cairo 1984.
 
14.
Wechsler D. Wechsler adult intelligence scale-revised manual. The Psychological Corporation, New York 1981.
 
15.
Wechsler D. Wechsler memory scale-revised manual. The Psychological Corp. Harcourt Brace Jovanovich, New York 1987; 138–141.
 
16.
Akman-Demir G, Serdaroglu, Tasçi B. Clinical patterns of neurological involvement in Behçet’s disease: evaluation of 200 patients: the Neuro-Behçet Study Group. Brain 1999; 122: 2171–2182, DOI: 10.1093/brain/122.11.2171.
 
17.
El-Najjar AR, El Masry NM, El-Shabrawy A, El-Gerby KM. Cognitive functioning in Egyptian Behçet’s disease patients: clinical, psychiatric, and brain MRI evaluation. Int J Advanc Res 2015; 3: 406–418.
 
18.
18 Urbain F, Hardy-Léger I, Adebs-Nasser G, et al. Psychiatric symptoms and cognitive disorders in Behçet’s disease: a single-center, cross-sectional study. J Clin Med 2023; 12: 3149, DOI: 10.3390/jcm12093149.
 
19.
Gündüz T, Emir Ö, Kürtüncü M, et al. Cognitive impairment in neuro-Behcet’s disease and multiple sclerosis: a comparative study. Int J Neurosci 2012; 122: 650–656, DOI: 10.3109/00207454.2012.704454.
 
20.
Erkol G, Vural M, Karantay F, et al. Event-related Potentials and Paced Auditory Serial Addition Test (PASAT) evaluation in Behçet’s syndrome with subclinical neural involvement. Nobel Medicus 2009; 5: 29–34, DOI: 10.5709/acp-0123-z.
 
21.
Altunkaynak Y, Usta Ş, Ertem DH, et al. Cognitive functioning and silent neurological manifestations in Behçet’s disease with ocular involvement. Noro Psikiyatr Ars 2018; 56: 173–177, DOI: 10.5152/npa.2017.19406.
 
22.
Zayed H, Effat D, Nawito Z, et al. Silent central nervous system involvement in Egyptian Behçet’s disease patients: clinical, psychiatric, and neuroimaging evaluation. Clin Rheumatol 2011; 30: 1173–1180, DOI: 10.1007/s10067-011-1725-2.
 
23.
Goodall J, Fisher C, Hetrick S, et al. Neurocognitive functioning in depressed young people: a systematic review and meta- analysis. Neuropsychol Rev 2018; 28: 216–231, DOI: 10.1007/s11065-018-9373-9.
 
24.
Rock PL, Roiser JP, Riedel WJ, Blackwell AD. Cognitive impairment in depression: a systematic review and meta-analysis. Psychol Med 2014; 44: 2029–2040, DOI: 10.1017/S0033291713002535.
 
25.
Castaneda AE, Tuulio-Henriksson A, Marttunen M, et al. A review on cognitive impairments in depressive and anxiety disorders with a focus on young adults. J Affect Disord 2008; 106: 1–27, DOI: 10.1016/j.jad.2007.06.006.
 
26.
Lupien SJ, Gillin CJ, Hauger RL. Working memory is more sensitive than declarative memory to the acute effects of corticosteroids: a dose-response study in humans. Behav Neurosci 1999; 113: 420–430, DOI: 10.1037//0735-7044.113.3.420.
 
27.
Brown ES, Chandler PA. Mood and cognitive changes during systemic corticosteroid therapy. Prim Care Companion J Clin Psychiatry 2001; 3: 17–21, DOI: 10.4088/pcc.v03n0104.
 
28.
De Alcubierre D, Ferrari D, Mauro G, et al. Glucocorticoids and cognitive function: a walkthrough in endogenous and exo­genous alterations. J Endocrinol Invest 2023; 46: 1961–1982, DOI: 10.1007/s40618-023-02091-7.
 
29.
Patten SB, Neutel CI. Corticosteroid-induced adverse psychia­tric effects: incidence, diagnosis and management. Drug Saf 2000; 22: 111–122, DOI: 10.2165/00002018-200022020-00004.
 
30.
Brown ES, J Woolston D, Frol A, et al. Hippocampal volume, spectroscopy, cognition, and mood in patients receiving corticosteroid therapy. Biol Psychiatry 2004; 55: 538–545, DOI: 10.1016/j.biopsych.2003.09.010.
 
31.
Keenan PA, Jacobson MW, Soleymani RM, et al. The effect on memory of chronic prednisone treatment in patients with systemic disease. Neurology 1996; 47: 1396–1402, DOI: 10.1212/wnl.47.6.1396.
 
32.
Brunner R, Schaefer D, Hess K, et al. Effect of corticosteroids on short-term and long-term memory. Neurology 2005; 64: 335–337, DOI: 10.1212/01.WNL.0000149523.35039.4C.
 
33.
Varney NR, Alexander B, MacIndoe JH. Reversible steroid dementia in patients without steroid psychosis. Am J Psychiatry 1984; 141: 369–372, DOI: 10.1176/ajp.141.3.369.
 
34.
Wolkowitz OM, Lupien SJ, Bigler ED. The “steroid dementia syndrome”: a possible model of human glucocorticoid neurotoxicity. Neurocase 2007; 13: 189–200, DOI: 10.1080/13554790701475468.
 
35.
Het S, Ramlow G, Wolf OT. A meta-analytic review of the effects of acute cortisol administration on human memory. Psychoneuroendocrinology 2005; 30: 771–784. DOI: 10.1016/ j.psyneuen.2005.03.005.
 
36.
de Quervain DJ, Roozendaal B, Nitsch RM, et al. Acute cortisone administration impairs retrieval of long-term declarative memory in humans. Nat Neurosci 2000; 3: 313–314, DOI: 10.1038/73873.
 
37.
Coluccia D, Wolf OT, Kollias S, et al. Glucocorticoid therapy-induced memory deficits: acute versus chronic effects. J Neurosci 2008; 28: 3474–3478, DOI: 10.1523/JNEUROSCI.4893-07.2008.
 
38.
Lupien SJ, Wilkinson CW, Brière S, et al. The modulatory effects of corticosteroids on cognition: studies in young human po­pulations. Psychoneuroendocrinology 2002; 27: 401–416, DOI: 10.1016/s0306-4530(01)00061-0.
 
39.
Abercrombie HC, Kalin NH, Thurow ME, et al. Cortisol variation in humans affects memory for emotionally laden and neutral information. Behav Neurosci 2003; 117: 505–516, DOI: 10.1037/0735-7044.117.3.505.
 
40.
Naber D, Sand P, Heigl B. Psychopathological and neuropsychological effects of 8-days’ corticosteroid treatment. A prospective study. Psychoneuroendocrinology 1996; 21: 25–31, DOI: 10.1016/0306-4530(95)00031-3.
 
41.
Brown ES, Suppes T, Khan DA, Carmody TJ III. Mood changes during prednisone bursts in outpatients with asthma. J Clin Psychopharmacol 2022; 22: 55–61, DOI: 10.1097/00004714-200202000-00009.
 
42.
Wolkowitz OM, Rubinow D, Doran AR, et al. Prednisone effects on neurochemistry and behavior. Arch Gen Psychiatry 1990; 47: 963–968, DOI: 10.1001/archpsyc.1990.01810220079010.
 
43.
Abdel-Nasser AM, Ghaleb RM, Mahmoud JA, et al. Association of anti-ribosomal P protein antibodies with neuropsychiatric and other manifestations of systemic lupus erythematosus. Clin Rheumatol 2008; 27: 1377–1385, DOI: 10.1007/s10067-008-0921-1.
 
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
eISSN:2084-9834
ISSN:0034-6233
Journals System - logo
Scroll to top